唑来膦酸对高龄女性骨质疏松症患者骨密度和血清骨转换标志物的影响

发布时间：2018-06-27 21:51

  本文选题：唑来膦酸 + 骨质疏松　； 参考：《中国新药与临床杂志》2017年08期

【摘要】：目的了解唑来膦酸对高龄女性骨质疏松症患者骨密度(BMD)和血清骨转换标志物(BTMs)的影响。方法纳入年龄≥80岁的女性骨质疏松症患者30例,予碳酸钙D3咀嚼片1片,嚼服,bid;骨化三醇胶丸0.25μg,po,bid。12个月后予唑来膦酸5 mg静脉滴注1次,并维持原补钙和活性维生素D方案。检测入组时、唑来膦酸治疗前、治疗后12个月患者血清Ⅰ型胶原交联C-末端肽(CTX)、Ⅰ型前胶原N-端前肽(PINP)和骨钙素(OC)的水平,同时测量股骨颈、总髋部和腰椎1-4处的BMD。观察应用唑来膦酸72 h内不良反应发生情况。结果与入组时比较,唑来膦酸治疗前患者血清CTX、PINP和OC水平有所升高,股骨颈、总髋部和腰椎1-4处的BMD有所降低,但大部分指标差异无显著意义(P0.05)。唑来膦酸治疗后12个月,患者血清CTX、PINP和OC水平均明显低于入组时和唑来膦酸治疗前(P0.05或P0.01),而股骨颈、总髋部和腰椎1-4处的BMD则显著高于入组时和唑来膦酸治疗前(P0.05或P0.01)。未见严重不良反应发生。结论唑来膦酸能降低高龄女性骨质疏松症患者的血清BTMs水平,并提高BMD。
[Abstract]:Objective to investigate the effects of zoledronic acid on bone mineral density (BMD) and serum bone turnover markers (BTMs) in elderly women with osteoporosis. Methods Thirty female osteoporosis patients aged more than 80 years were treated with calcium carbonate D3 chewable tablet and chewed with bidbid.Osteotriol colloidal pill 0.25 渭 g popobidbid.12 months later, Zoledronic acid 5mg was given intravenously, and the original calcium supplement and active vitamin D regimen were maintained. Serum levels of type I collagen cross-linked C-terminal peptide (CTX), type 鈪，

本文编号：2075396